MRSA Eradication of Newly Acquired Lower Respiratory Tract Infection in Cystic Fibrosis

Overview

Journal ERJ Open Res

Specialty Pulmonary Medicine

Date 2016 Oct 13

PMID 27730175

Citations 11

Authors

Emilie Vallieres

Jacqueline C Rendall

John E Moore

John McCaughan

Anne I Hoeritzauer

Michael M Tunney

Joseph Stuart Elborn

Damian G Downey

Affiliations

Soon will be listed here.

Abstract

UK cystic fibrosis (CF) guidelines recommend eradication of methicillin-resistant (MRSA) when cultured from respiratory samples. As there is no clear consensus as to which eradication regimen is most effective, we determined the efficacy of eradication regimens used in our CF centre and long-term clinical outcome. All new MRSA positive sputum cultures (n=37) that occurred between 2000 and 2014 were reviewed. Eradication regimen characteristics and clinical, microbiological and long-term outcome data were collected. Rifampicin plus fusidic acid was the most frequently used regimen (24 (65%) out of 37 patients), with an overall success rate of 79% (19 out of 24 patients). Eradication failure was more likely in patients with an additional MRSA-positive peripheral screening swab (p=0.03) and was associated with worse survival (p=0.04). Our results demonstrate the feasibility and clinical benefits of MRSA eradication. As peripheral colonisation was associated with lower eradication success, strategies combining systemic and topical treatments should be considered to optimise outcomes in CF patients.

Citing Articles

Brazilian guidelines for the pharmacological treatment of the pulmonary symptoms of cystic fibrosis. Official document of the Sociedade Brasileira de Pneumologia e Tisiologia (SBPT, Brazilian Thoracic Association).

Athanazio R, Tanni S, Ferreira J, Dalcin P, Fuccio M, Esposito C J Bras Pneumol. 2023; 49(2):e20230040.

PMID: 37194817 PMC: 10171269. DOI: 10.36416/1806-3756/e20230040.

Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis.

Lo D, Muhlebach M, Smyth A Cochrane Database Syst Rev. 2022; 12:CD009650.

PMID: 36511181 PMC: 9745639. DOI: 10.1002/14651858.CD009650.pub5.

Cystic Fibrosis: Recent Insights into Inhaled Antibiotic Treatment and Future Perspectives.

Taccetti G, Francalanci M, Pizzamiglio G, Messore B, Carnovale V, Cimino G Antibiotics (Basel). 2021; 10(3).

PMID: 33810116 PMC: 8004710. DOI: 10.3390/antibiotics10030338.

Molecular characterisation of methicillin-resistant from chronically colonised cystic fibrosis paediatric patients in Brazil.

Rodrigues D, Lima D, Cohen R, Marques E, Leao R Epidemiol Infect. 2020; 148:e149.

PMID: 32450935 PMC: 7374800. DOI: 10.1017/S0950268820001156.

Infection prevention and chronic disease management in cystic fibrosis and noncystic fibrosis bronchiectasis.

Lommatzsch S Ther Adv Respir Dis. 2020; 14:1753466620905272.

PMID: 32160809 PMC: 7068740. DOI: 10.1177/1753466620905272.

References

Dasenbrook E, Checkley W, Merlo C, Konstan M, Lechtzin N, Boyle M . Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA. 2010; 303(23):2386-92. DOI: 10.1001/jama.2010.791. View

Vanderhelst E, De Wachter E, Willekens J, Pierard D, Vincken W, Malfroot A . Eradication of chronic methicillin-resistant Staphylococcus aureus infection in cystic fibrosis patients. An observational prospective cohort study of 11 patients. J Cyst Fibros. 2013; 12(6):662-6. DOI: 10.1016/j.jcf.2013.04.009. View

Lo D, Hurley M, Muhlebach M, Smyth A . Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis. Cochrane Database Syst Rev. 2015; (2):CD009650. DOI: 10.1002/14651858.CD009650.pub3. View

Vanderhelst E, De Meirleir L, Verbanck S, Pierard D, Vincken W, Malfroot A . Reply to 'Methicillin-resistant Staphylococcus aureus'. J Cyst Fibros. 2012; 12(2):183. DOI: 10.1016/j.jcf.2012.08.002. View

Hall H, Gadhok R, Alshafi K, Bilton D, Simmonds N . Eradication of respiratory tract MRSA at a large adult cystic fibrosis centre. Respir Med. 2015; 109(3):357-63. DOI: 10.1016/j.rmed.2015.01.013. View

Sawicki G, Rasouliyan L, Pasta D, Regelmann W, Wagener J, Waltz D . The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis. Pediatr Pulmonol. 2008; 43(11):1117-1123. DOI: 10.1002/ppul.20914. View

. ESCMID Consensus concerning MRSA. Clin Microbiol Infect. 2009; 15 Suppl 7:1-52. DOI: 10.1111/j.1469-0691.2009.03113.x. View

Liu C, Bayer A, Cosgrove S, Daum R, Fridkin S, Gorwitz R . Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011; 52(3):e18-55. DOI: 10.1093/cid/ciq146. View

Doe S, McSorley A, Isalska B, Kearns A, Bright-Thomas R, Brennan A . Patient segregation and aggressive antibiotic eradication therapy can control methicillin-resistant Staphylococcus aureus at large cystic fibrosis centres. J Cyst Fibros. 2010; 9(2):104-9. DOI: 10.1016/j.jcf.2009.11.009. View

10.

Ammerlaan H, Kluytmans J, Wertheim H, Nouwen J, Bonten M . Eradication of methicillin-resistant Staphylococcus aureus carriage: a systematic review. Clin Infect Dis. 2009; 48(7):922-30. DOI: 10.1086/597291. View

11.

Doring G, Flume P, Heijerman H, Elborn J . Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros. 2012; 11(6):461-79. DOI: 10.1016/j.jcf.2012.10.004. View

12.

Dasenbrook E, Merlo C, Diener-West M, Lechtzin N, Boyle M . Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med. 2008; 178(8):814-21. DOI: 10.1164/rccm.200802-327OC. View

13.

Solis A, Brown D, Hughes J, van Saene H, Heaf D . Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: An eradication protocol. Pediatr Pulmonol. 2003; 36(3):189-95. DOI: 10.1002/ppul.10231. View

14.

Vanderhelst E, De Meirleir L, Verbanck S, Pierard D, Vincken W, Malfroot A . Prevalence and impact on FEV(1) decline of chronic methicillin-resistant Staphylococcus aureus (MRSA) colonization in patients with cystic fibrosis. A single-center, case control study of 165 patients. J Cyst Fibros. 2011; 11(1):2-7. DOI: 10.1016/j.jcf.2011.08.006. View

15.

Cox D, Kelly C, Rush R, OSullivan N, Canny G, Linnane B . The impact of MRSA infection in the airways of children with cystic fibrosis; a case-control study. Ir Med J. 2012; 104(10):305-8. View

16.

Kerem E, Reisman J, Corey M, Canny G, Levison H . Prediction of mortality in patients with cystic fibrosis. N Engl J Med. 1992; 326(18):1187-91. DOI: 10.1056/NEJM199204303261804. View

17.

Jennings M, Boyle M, Weaver D, Callahan K, Dasenbrook E . Eradication strategy for persistent methicillin-resistant Staphylococcus aureus infection in individuals with cystic fibrosis--the PMEP trial: study protocol for a randomized controlled trial. Trials. 2014; 15:223. PMC: 4068380. DOI: 10.1186/1745-6215-15-223. View

18.

Serisier D, Jones G, Carroll M . Eradication of pulmonary methicillin-resistant staphylococcus aureus (MRSA) in cystic fibrosis with linezolid. J Cyst Fibros. 2004; 3(1):61. DOI: 10.1016/j.jcf.2003.12.010. View

19.

Burdge D, Nakielna E, Noble M . Eradication of methicillin-resistant Staphylococcus aureus from the lower respiratory tract of patients with cystic fibrosis. Can J Infect Dis. 2012; 6(2):97-101. PMC: 3298058. DOI: 10.1155/1995/176396. View

20.

MacFarlane M, Leavy A, McCaughan J, Fair R, Reid A . Successful decolonization of methicillin-resistant Staphylococcus aureus in paediatric patients with cystic fibrosis (CF) using a three-step protocol. J Hosp Infect. 2006; 65(3):231-6. DOI: 10.1016/j.jhin.2006.10.011. View